300 related articles for article (PubMed ID: 30098869)
1. Design, synthesis and preclinical evaluation of 5-methyl-N
Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
3. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Cells.
Devambatla RK; Namjoshi OA; Choudhary S; Hamel E; Shaffer CV; Rohena CC; Mooberry SL; Gangjee A
J Med Chem; 2016 Jun; 59(12):5752-65. PubMed ID: 27213719
[TBL] [Abstract][Full Text] [Related]
5. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
6. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Zhang X; Raghavan S; Ihnat M; Thorpe JE; Disch BC; Bastian A; Bailey-Downs LC; Dybdal-Hargreaves NF; Rohena CC; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2014 Jul; 22(14):3753-72. PubMed ID: 24890652
[TBL] [Abstract][Full Text] [Related]
7. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
9. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
Choudhary S; Doshi A; Luckett-Chastain L; Ihnat M; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2021 Apr; 35():116061. PubMed ID: 33647840
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
11. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors.
Abd El-Mageed MMA; Eissa AAM; Farag AE; Osman EEA
Bioorg Chem; 2021 Nov; 116():105336. PubMed ID: 34530235
[TBL] [Abstract][Full Text] [Related]
13. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.
Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
15. N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Gangjee A; Kurup S; Ihnat MA; Thorpe JE; Disch B
Bioorg Med Chem; 2012 Jan; 20(2):910-4. PubMed ID: 22204741
[TBL] [Abstract][Full Text] [Related]
16. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
17. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents.
Ghith A; Youssef KM; Ismail NSM; Abouzid KAM
Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
20. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
